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Abstract
Although hypertension and aortic stenosis are the most common cardiovascular diseases, the
impact of hypertension on the natural history of aortic stenosis, the structure and function of
the left ventricle, the assessment of valve defect severity and its progression are not fully
understood. Hypertension not only can modify the exploratory findings of aortic stenosis, but
may also interfere with the assessment of severity, and even have an impact on patients
outcome. In the absence of specific cohort studies, the nature of the association between aortic
stenosis and high blood pressure is not clear and the published results are often contradictory.
Unknown is the true frequency of both conditions, the rules of diagnosis and the treatment
itself. (Cardiol J 2013; 20, 1: 4–10)
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Introduction
Aortic stenosis (AS) is the most common val-
vular heart disease in adults. It is the third cause of
cardiovascular disease after hypertension and co-
ronary artery disease. Nowadays, AS is generally
caused by a progressive calcification of the aortic
leaflets and due to increasing life expectancy in the
general population, this form of valvular heart dis-
ease is now regarded as the coming plague of the
21st century [1].
Although hypertension and AS are the most
common cardiovascular disease, the impact of hy-
pertension on the natural history of AS, the struc-
ture and function of the left ventricle (LV), the as-
sessment of the degree of defect and its progres-
sion are not fully understood [2]. The problems
associated with coexistence of both diseases are not
a frequent subject of studies, what is more, the pub-
lished results are often contradictory. Unknown is
the true frequency of the coexistence of both con-
ditions, the rules of diagnosis and the treatment.
Because of the prolongation of life span, we
should expect an increase in the incidence of AS in
patients with hypertension as well as the reverse
situation — more cases of hypertension in the group
of patients with AS.
What is the prevalence of hypertension
in patients with aortic stenosis?
The first question without answer is the fre-
quency of coexistence of both diseases in popula-
tion. The true coexistence of AS and hypertension
is difficult to estimate [3–13]. Only few population-
-based studies on a representative group that would
allow estimate the frequency of the coexistence of
both diseases were carried out. The assessment of
diagnoses with which the patients were discharged
from hospitals in 1993–1999 in Ireland (3.39 million
cases) estimated that hypertension was the first or
subsequent diagnosis in 6.2% of all patients, and AS
in 0.33% — both diseases were observed in 0.07%
of cases. Hypertension was found in 21% of patients
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with AS, but AS only in 1.1% of patients with hy-
pertension [12].
Most information about the coexistence of both
diseases can be found in the studies concerning the
patients referred for surgical treatment in case of
symptomatic AS or observed in case of asymptoma-
tic or insignificant defect. In these incidence of
hypertension in patients with AS varies from 33%
to 90% [2, 4, 13–15]. The highest incidence de-
scribed in the literature was reported in symptom-
atic patients with moderate/significant AS, in whom
myocardial fibrosis was observed prospectively.
Hypertension was found in 80% of patients with
moderate and 90% with significant AS with low
transvalvular pressure gradient with preserved LV
systolic function — the majority of these patients
were older than 70 years [15]. In patients in whom
the effect of cholesterol-lowering drugs on the pro-
gression of AS was observed, hypertension was
found more often than in the population without
heart defects [16]. Also comparison of the frequen-
cy of hypertension among men and women with AS
provide conflicting results. In some studies hyper-
tension occurs in patients with AS more frequently
among women (46%) than men (29%) [17].
There is no doubt that in recent years, due to
the aging population, prolonged survival and in-
creased accessibility to modern methods of diagno-
sis, frequency of diagnoses of hypertension in pa-
tients with AS significantly increased [18]. Both
diseases may have common pathophysiological
mechanism, may be coincidence of common diseas-
es or may be closely linked. Moreover, there is the
evidence that hypertension is an independent fac-
tor in the development of degenerative forms of AS
in elderly [19, 20].
Does hypertension affect
the diagnosis of aortic stenosis?
Hypertension is a disease in which symptoms
usually occur late, at the onset of organ damage. It
is often detected during random pressure measure-
ments. Aortic stenosis is also asymptomatic for
many years and it happens that diagnosis of valve
disease is made on the basis of typical murmur or
ECHO examination performed of other indications.
In case of a significant defect and appearance
of typical symptoms of AS (angina, symptoms of low
cardiac output or heart failure) indication for sur-
gery is mandatory [21].
In patients with AS and hypertension, greater
hypertrophy, increased wall thickness and LV mass
may lead to the development of symptoms, partic-
ularly shortness of breath at a lower stage of valve
defect, lower transvalvular gradients and higher
aortic valve area [22]. Here another question about
the treatment of such patients arises — recommen-
dations of Cardiological Societies do not contain
guidance on these particular patients. There is no
answer to the question of whether such patients
should be operated earlier? If not — what parame-
ters are the best to follow-up in this case in the fu-
ture? Are we to manage patients for surgery when
the gradient increases and the valve area signifi-
cantly decrease, and in the meantime to treat pa-
tients conservatively despite typical symptoms?
On the other hand, in advanced AS, the diag-
nosis of hypertension may be easily overlooked —
most of the authors point out that the value of in-
creased blood pressure with the progress of AS
decreases. What is more, the older textbooks of
cardiology even pay attention to the fact that in-
creased pressure in patients with significant AS is
very rare [23, 24].
Another problem is related to the physical exa-
mination. The auscultatory phenomena in AS are
highly characteristic. It should be emphasized that
the cardiac auscultation is the cheapest and the
most diagnostic method, yet, unfortunately, it is
very often neglected in fascination of state-of-the
art techniques. The heart murmur of AS is a typi-
cal crescendo-decrescendo (diamond-shaped) ejec-
tion murmur with no heard second tone. The mur-
mur is sometimes accompanied by a systolic thrill.
It is usually harsh, often even musical, and is most
audible over the aortic area. The radiation of the
murmur is quite extensive over both carotid arter-
ies, left supra- and intraclavicular fosse and jugular
fossa. It may also be heard over the back. Some-
times the murmur becomes quiet over the middle
portion of the sternum and reappears at the apex.
In the elderly, this may be the only area where it is
heard [21, 23, 25, 26].
All the more surprising is the fact, that in those
patients with hypertension, who have been under
the care of doctors for many years; AS is often dia-
gnosed at a very advanced stage, when clinical
symptoms appear. By this time, unfortunately, in
hypertensive patients murmur is treated as irrele-
vant ejection murmur and this may lead to delay in
the diagnosis of disease. It happens sometimes, that
AS is recognized with the change of physician.
On the other hand, this condition can also be
explained by the fact that hypertension can modify
the physical examination findings of AS, particularly
in the elderly patients. The characteristic explor-
atory findings of AS are all influenced by peripher-
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al aortic impedance, valve reflections, poststeno-
sic aortic dilatation and vessel stiffness. Therefore,
coexisting hypertension may result in a carotid
pulse with a rapid upstroke and normal amplitude,
as well, as in a diminished murmur or a near nor-
mal second cardiac sound [3]. It should be also re-
membered that in older patients location of the
murmur of AS is unusual — in 25% the murmur may
be heard only at the apex [3, 11, 26].
Because of this limitation, the echocardio-
graphic examination should never be obviated if
a systolic murmur is heard, or if AS is suspected in
a hypertensive patient.
What is the effect of hypertension
on echocardiographic assessment
of aortic stenosis?
Echocardiography confirms the diagnosis and
the severity of AS. The examination should in-
clude: the measurement of blood flow velocity
through the valve (Vmax), the definition of the
pressure gradients (PG) through the valve (peak
PG and mean PG), the calculation of the aortic
valve area (AVA), AVA indexed in relation to the
body surface area (AVA//BSA) and the parameters
describing the degree of left ventricular hypertro-
phy (LVH) and LV function [21, 26–29]. The mor-
phology of the valve is also important (presence
of significant calcifications). Hemodynamically sig-
nificant AS is characterized by: AVA < 1 cm2,
AVA/BSA < 0.6 cm2/m2, Vmax > 4 m/s and mean
PG > 40 mm Hg.
Theoretically, hypertension can lead to in-
creased peripheral resistance, it may also reduce
the vulnerability of blood vessels, worsening LV
function and cause changes in flow through the aor-
tic valve [7, 30]. In an experimental model, in vitro,
echocardiographic and hemodynamic assessment of
the effect of hypertension on the AVA and trans-
valvular flow parameters showed no flow changes
secondary to changes in afterload [29]. On the oth-
er hand, significant changes in afterload caused by
drugs or physical activity can modify the LV func-
tion, the transvalvular gradient and the volume flow
[31]. This effect was confirmed in vivo in a porcine
heart model. Hypertension leads to lower the trans-
valvular gradients — explained the mechanism of
inheritance dependency of the gradient flow asso-
ciated with increased systemic resistance [11, 24,
32]. The effects of hypertension on the assessment
of severity of AS in these experimental researches
were focused on the influence of sudden changes
in load (pressure) — as we know the impact of he-
modynamic changes caused by chronic hyperten-
sion may be different [21].
Some authors suggest that the significance of
valve stenosis may be masked by coexisting hyper-
tension, especially by sudden changes and that the
defect may be underestimated. Hence the severity
of AS at high blood pressure should be interpreted
with caution. In the ESC (2012) recommendation, in
the part describing the echocardiographic assessment
of AS, there is only one sentence informing that when
hypertension is present, the severity should be reas-
sessed when the patient is normotensive [21].
The recommendations of EAE/ASE (2009) in-
clude a few sentences about the measurement in
patients with hypertension [34]. The experts note
that “although a recent in vitro study has demonstrat-
ed that systemic pressure may not directly affect
gradient and valve area measurements, increa-
sing LV pressure load may cause changes in
ejection fraction and flow. The presence of hyper-
tension may therefore primarily affect flow and gra-
dient but less AVA measurements. Nevertheless,
evaluation of AS severity with uncontrolled hyper-
tension may not accurately reflect disease severity.
Thus control of blood pressure is recommended be-
fore echocardiographic evaluation, whenever possi-
ble”. The experts stress that the echocardiographic
report should always include a blood pressure mea-
surement recorded at the time of the examination.
Left ventricular hypertrophy
in aortic stenosis: How much
important is hypertension?
Aortic stenosis, like hypertension is a gradu-
ally progressive disease, asymptomatic for many
years of the clinical course — both are examples of
diseases that cause LV overload and lead to LVH.
However, the response to these two conditions
does not proceed in the same way.
Aortic stenosis creates an obstruction to blood
flow from the LV to the aorta which lead to LV pres-
sure overload hypertrophy. The increase in pres-
sure in the LV, myocardial hypertrophy and pro-
longed ejection time are basic compensatory mech-
anisms of AS, which make asymptomatic course of
the disease for many years [21]. The LV adapts to
elevated systolic blood pressure by means of con-
centric hypertrophy, which leads to thickening of
the walls without increasing the LV cavity [35].
Left ventricular hypertrophy in arterial hyper-
tension, in response to different types of overload
and LV geometry change, in the case of high blood
pressure may take the form of concentric remodel-
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ing, concentric or eccentric hypertrophy [35–37].
The adaptation of the LV is modified on the one
hand the stage of hypertension, and type of medi-
cation efficacy and its duration, and, on the other,
different clinical or hemodynamic factors — not
without significance is the influence of genetic fac-
tors. The changes usually occur in 30–50% of pa-
tients, most of whom demonstrate eccentric hyper-
trophy, a different type of hypertrophy usually found
in AS [36, 37].
In case of AS and hypertension we are dealing
with two diseases, which generate LVH — in case
of AS it is concentric hypertrophy and in case of
hypertension — volume, pressure or mixed over-
load is possible — in practice it is difficult to sepa-
rate the effect associated with both diseases. Aor-
tic stenosis usually leads to concentric remodeling
or concentric hypertrophy, regardless of the pres-
ence or not of hypertension [2, 4, 22].
The effect of hypertension on the size of LVH
with coexisting hypertension is rarely described in
the literature — less than it would indicate the fre-
quency of coexistence of both diseases [2, 4, 14, 22,
24, 30]. Some authors pointed out the significant
effect of hypertension on the degree of hypertro-
phy, others did not show any difference in the de-
gree of remodeling in the coexistence of these two
conditions [2, 14, 22, 24, 30]. In the absence of pub-
lished data which describe the impact of hyperten-
sion on electrocardiography evaluation of LVH in
patients with AS, we apply the same electrocardio-
graphic criteria as in isolated LVH.
In a large group of patients (1720 patients from
173 European centers) with asymptomatic AS
(Vmax ≥ 2.5 m/s and £ 4 m/s) enrolled in a study
evaluating the impact of simwastatin and ezetimibe
on the course of valve disease, the echocardiograph-
ic results were compared among the patients with/
/without coexistence of hypertension. In patients
with hypertension there were more female patients,
they were older and more obese. Compared to pa-
tients without high blood pressure, LVH, relative
wall thickness ratio and wall thickness were ob-
served more frequently — but what is interesting,
eccentric hypertrophy was the most frequently ob-
served type of hypertrophy, both in the group with
hypertension and without it (concentric hypertro-
phy and concentric remodeling was recognized only
in 8% in both) [14, 38].
We do not know the answer to the question
which disease affects more on the LVH, arterial hy-
pertension or AS? Garcia et al. [6] in the experimen-
tal model proved that in mild/moderate AS hyper-
tension was a dominant factor in the remodeling of
the LV, while in a significant stenosis effect of hyper-
tension was less marked — the impact of AS far ex-
ceeded the impact of hypertension [6]. In AS chang-
es are initially related to increased wall thickness,
while the volume of the cavity does not change; in case
of the coexistence of both diseases the dominant in-
fluence of hypertension determines the type of hy-
pertrophy [37]. These studies confirmed the obser-
vations of a group of patients with hypertension and
AS [4]. Moreover, the impact of hypertension on LVH
was more marked in women [35, 39–42].
Asymmetric septal hypertrophy is usually seen
in patients with hypertrophic cardiomyopathy. In
people with hypertension, asymmetric septal hyper-
trophy is sometimes recognized in early stages of
the LV adaptation. In patients with AS asymmetri-
cal hypertrophy affects the extent of surgery. In the
multivariate analysis performed in asymptomatic
patients with AS arterial hypertension was the in-
dependent risk factor of asymmetric septal hyper-
trophy, regardless of severity of the defect [43].
From a theoretical point of view, LVH in AS is
a beneficial compensatory response to excessive af-
terload, aimed at normalization of systolic stress in
the wall of the LV [37]. However, for high blood
pressure is less favorable the prognosis in patients
who develop LVH compared to those with the nor-
mal LV geometry. In this group a higher mortality,
higher incidence of coronary syndromes, ventricu-
lar arrhythmias and sudden cardiac death are ob-
served. The risk of cardiovascular complications
increases with the degree of LVH. Type of LV re-
modeling in hypertension is also associated with
increased cardiovascular complications — 11% of
the complications encountered in patients with nor-
mal LV, 15% when the current is concentric remod-
eling, 23% in patients with eccentric hypertrophy
and 31% of the states concentric hypertrophy [44].
It seems that the coexistence of these two en-
tities, which often results in higher LVH, is associ-
ated with the increased risk of cardiovascular com-
plications greater than in case of defects of isolated
hypertension [35].
Aortic valve replacement:
When to perform in patients with
aortic stenosis and hypertension?
According to the current ESC and ACC/AHA
guidelines, a decision to perform AVR should be
based on two criteria: diagnosis of a severe AS
(AVA < 1.0 cm2, AVA/BSA < 0.6 cm2/m2, mean
PG > 40 mm Hg with preserved LV systolic function)
and presence of symptoms [21, 26]. There are often
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discrepancies between the severity of the stenosis
and the symptomatic status. Some patients become
symptomatic although they have only moderate AS,
whereas others remain symptomatic despite the
presence of severe stenosis. A patient having
a moderate AS and concomitantly a moderate hyper-
tension may have indeed higher LV afterload and
more LVH than a patient with severe AS and nor-
mal blood pressure [6]. When AS is accompanied
by hypertension, the LV faces a double burden —
valvular and vascular, so symptoms may occur ear-
lier, before echocardiographic parameters will in-
dicate significant AS.
The recommendations don’t show any guid-
ance on how to handle this case. In case of asymp-
tomatic AS in the recommendations of the ESC
class IIb indication for surgery is important LVH
(> 15 mm), not caused by hypertension. As mentioned
above, in case of a substantial defect and hyperten-
sion, stenosis is the strongest factor influencing
LVH — maybe also in this group of patients the
indications for surgical treatment should be consid-
ered earlier — to these question there is no answer.
In recent years, at congresses and in pages of the
cardiology literature the proceedings (whether
treated by surgery) in patients with AS, in whom
the preserved LV systolic function and significant-
ly reduced valve area is not adequately recorded
with high PG (low flow, low gradient AS with pre-
served ejection fraction) have been discussed. This
group includes patients with small left chambers,
and a large muscle hypertrophy, especially women
— is not this just the effect of the impact of con-
comitant hypertension?
How to treat hypertension
in patients with aortic stenosis?
As mentioned above, the effective treatment of
symptomatic, significant AS is aortic valve replace-
ment. Conservative treatment of advanced stage in
case of contraindications to surgery or lack of patient
consent is very difficult. Usually, it is effective for
a very short period of time. Often, it may be harmful
[21]. Even the severe valve defect, without symp-
toms, does not need pharmacological treatment.
On the other hand, even moderately, and poorly
controlled hypertension can significantly accelerate
and enhance LVH and reduce the benefits associ-
ated with the valve surgery in the future [6, 44]. The
recommendations of the ESC experts have pointed
out that in case of significant AS hypertension
should be treated with caution. The negative ino-
tropic drugs such as beta-blockers should be avoid-
ed. There is also concern that vasodilatators can lead
to reduction in the coronary perfusion pressure [21].
Furthermore, the best drug for lowering blood
pressure in the presence of an AS has not been es-
tablished. A specific potential benefit has been sug-
gested for the inhibitors of angiotensin converting
enzyme (ACE), since ACE activity has been involved
not only in unfavorable LV remodeling response, but
also in the progression of valve deterioration. ACE
inhibitors, that prolong life in most cases of conges-
tive heart failure, like other vasodilatators, has been
classically considered contraindicated in AS, because
of their potentially hazardous effect or related to the
risk of decreasing coronary perfusion pressure in this
population of patients and may exacerbate symp-
toms. Cardiac output in severe AS can not be in-
creased because of stenotic valve. Decrease in pe-
ripheral resistance increases the transvalvular gra-
dient, leads to a drop in blood pressure, which can
be fatal. The recent retrospective studies, although
not planned to assess the safety of this drug in AS,
showed that the daily practice of ACE inhibitors is
widely used, because of concomitant hypertension
and is well tolerated. In the SCOPE-AS study symp-
tomatic patients with significant stenosis and normal
LV systolic function, who were not candidates for
surgical treatment, were randomized to the treat-
ment with enalapril or placebo. The drug was well
tolerated, although patients with poor LV function
presented a tendency to hypotension more often.
Similarly, the administration of ACE inhibitors in
patients with moderate AS, despite lowering blood
pressure and increase of the PG, did not result in
deterioration of exercise tolerance and clinical symp-
toms. These observations suggest that ACE inhibi-
tors may be used with caution in the treatment of
hypertension in patients with AS. If they had been
used before the diagnosis of AS with heart failure,
hypertension or diabetic nephropathy and had been
well tolerated by the patient, they should not be dis-
continued [21, 45–48]. Diuretic in AS should be used
only in volume overload. The excessive preload re-
duction may lead to deterioration of the LV filling,
reduced cardiac output and blood pressure. Patients
with significant AS are at risk for the occurrence of
these adverse events [21, 49].
What is the hypertension’s influence on
early and late results of the surgical
treatment of aortic stenosis?
Despite such frequent coexistence of both dis-
eases little is known about the impact of hyperten-
sion on early and late results of the surgical treat-
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ment and the pharmacological management after
aortic valve replacement. The only effective treat-
ment of AS is aortic valve replacement [21, 26]. The
effect of concomitant hypertension on long-term
fate of patients after aortic valve replacement is not
fully understood [50–57].
The implantation of an artificial valve elimi-
nates the systolic overload associated with AS, but
the load associated with hypertension remains [58].
This explains why patients with hypertension may
still have important LVH despite the valve replace-
ment or had worse LVH reduction after the surgery.
Here arises another question about monitor-
ing the effectiveness of the pharmacological treat-
ment of hypertension in patients after aortic valve
replacement. We don’t know, if like in the general
population, the treatment of hypertension in this
group is well controlled; there is lack of studies on
that subject, beyond the announcement many years
ago, in which hypertension was treated correctly
only in 8 of 43 patients [57].
Another question concerns the impact of hy-
pertension on the rate of biological prostheses de-
generation — there is a lack of data on this subject,
what will be the impact of hypertension on long-
term observation of patients after transaortic valve
implantation [19, 20].
Summary
Systemic hypertension, like AS, is nowadays
a frequent finding due to increase in life expectancy
and aging of population. It is expected that the dia-
gnosis of AS in patients with hypertension will
occur more frequently.
The more research is needed that will clarify the
answers to the questions above, especially with the
use of modern diagnostic methods, the dynamic
growth of which was seen in recent years [58–60].
These facts need to be considered for an adequate
diagnosis and management of patients with AS.
It is also important to note that hypertension,
on one hand, is well established risk for cardiovas-
cular events in the general population, and, on the
other, is one of the factors considered to be esca-
lating progression of defects but the treatment in
the coexistence of both diseases is not easy.
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